INTRODUCTION {#S1}
============

RNA polymerase (pol) III transcribes genes that encode a variety of small untranslated RNAs, including tRNAs, 5S rRNAs, and U6 RNAs ([@R37]). RNA pol III products play important roles in protein synthesis, protein trafficking, transcription elongation, and RNA processing. The rate of transcription is tightly regulated to correspond to the metabolic and proliferative demands of cells. Maf1, initially identified in yeast ([@R4]; [@R38]), associates with RNA pol III to inhibit transcription ([@R13]). In addition to Maf1-mediated repression of RNA pol III-dependent genes, mammalian Maf1 is recruited to select RNA pol II-dependent gene promoters to repress ([@R22]; [@R26]; [@R27]; [@R31]) or activate ([@R27]) transcription. Maf1 negatively regulates lipogenic enzyme gene expression and intracellular lipid accumulation both *in vitro* and *in vivo* ([@R24]; [@R31]). This function is conserved as Maf1 controls lipid homeostasis in *C. elegans* ([@R24]). Given that deregulation of Maf1-targeted genes such as tRNAs and 5S rRNAs ([@R21]) and lipogenic genes ([@R3]) are hallmarks of transformed cells and human cancers, this implicated a potential tumor suppressor role for Maf1. Accordingly, studies revealed that Maf1 inhibits cellular transformation and tumorigenesis and its expression is diminished in human liver cancer ([@R27]; [@R31]). Enhanced RNA pol III-dependent transcription is necessary to drive oncogenesis ([@R23]), and emerging evidence supports the idea that alterations in the expression of specific tRNAs can drive cell proliferation, tumor growth, and metastasis ([@R10]; [@R16]; [@R18]). In addition, recent studies implicate a role for RNA pol III-mediated transcription in longevity ([@R15]).

In contrast to what is known about the function of Maf1 in repressing oncogenesis, little is known about its potential role in other biological processes. Emerging studies are revealing that mutations in RNA pol III and its transcription components are associated with various human disorders ([@R6]; [@R11]; [@R12]; [@R17]; [@R20]; [@R36]), yet how this transcription process or Maf1 might regulate developmental programs and cell fate determination is not yet known. We therefore examined a potential role for Maf1 in early development and cellular differentiation by using embryonic stem cells (ESCs). These cells have the capacity for prolonged self-renewal, and they are able to differentiate into a variety of specialized cell types ([@R33]; [@R45]). We find that Maf1 protein expression is substantially reduced as both human ESCs (hESCs) and mouse ESCs (mESCs) differentiate into embryoid bodies (EBs) containing the three germ layers, coinciding with enhanced RNA pol III transcript expression. However, although Maf1 does not regulate ESC self-renewal, cellular Maf1 concentrations affect the ability of these cells to form the mesoderm germ layer. Upon further examination of the terminal differentiation of these cells into adipocytes, we find that Maf1 enhances the expression of the central regulators of adipogenesis, PPARγ and C/EBPα ([@R35]; [@R34]), to facilitate this process in mESCs, 3T3-L1 preadipocytes, and mouse embryo fibroblasts (MEFs). Importantly, we find that Maf1-mediated repression of RNA pol III-dependent gene expression contributes to its ability to induce adipogenesis. Adipogenesis was enhanced by chemical inhibition of RNA pol III as well as by downregulation of the RNA pol III-specific transcription factor Brf1. RNA sequencing (RNAseq) analysis of cells undergoing adipogenesis revealed that altered RNA pol III-dependent transcription produced select changes in gene expression. Maf1 downregulation altered transcripts that were concurrently upregulated by Brf1 knockdown and inhibitor treatment. These changes enriched for a gene expression signature encompassing adipocyte and lipid metabolism. RNA pol III-mediated transcription repression decreased expression of long non-coding (lnc) H19 RNA and Wnt6, consistent with their previously identified roles in negatively regulating adipogenesis. These results identify an unexpected role for RNA pol III-mediated transcription in controlling adipocyte differentiation through its modulation of specific RNA pol II-transcribed genes.

RESULTS {#S2}
=======

Maf1 Promotes the Induction of mESCs into Mesoderm {#S3}
--------------------------------------------------

Maf1 expression was analyzed in human and mESCs and after they were programmed to differentiate into EBs. Maf1 protein expression was relatively high in both hESCs and mESCs but substantially decreased as the cells differentiated into EBs ([Figures 1A and 1C](#F1){ref-type="fig"}). This occurred without a discernible change in Maf1 mRNA ([Figures 1B and 1D](#F1){ref-type="fig"}) suggesting that Maf1 is regulated post-transcriptionally during this process. Consistent with the decrease in Maf1 protein during differentiation, corresponding increases in the Maf1-targeted RNA pol III-dependent transcripts pre-tRNA^Leu^ and U6 RNA were observed as the ESCs differentiated into EBs. To determine whether Maf1 is required for mESC self-renewal, we reduced its expression using lentiviral delivery of two different short hairpin RNAs (shRNAs) ([Figure 1E](#F1){ref-type="fig"}). Maf1 knockdown in these cells resulted in an increase in U6 RNA ([Figure 1F](#F1){ref-type="fig"}), indicating that Maf1 is functioning to repress transcription in these cells. However, cell accumulation rates were unaffected upon decreased Maf1 expression ([Figure 1I](#F1){ref-type="fig"}). Examination of markers for self-renewal by immunostaining of SSEA1, histochemical staining of alkaline phosphatase, and RT-qPCR analysis of mRNAs for Sox2, Nanog, and Oct4 revealed that there were no significant changes in these markers when Maf1 expression was decreased ([Figures 1G and 1H](#F1){ref-type="fig"}). Thus, altered Maf1 expression does not affect mESC self-renewal or the proliferative capacity of mESCs.

We next assessed whether Maf1 was involved in maintaining mESC pluripotency and the ability of these cells to differentiate into EBs that constitute the three primary germ layers. Examining the expression of markers that specify endoderm (Gata6 and Gata4), mesoderm (T and Mesp1), and ectoderm (Nestin and Sox1) revealed that decreased Maf1 expression in mESCs had a relatively modest effect on the expression of endoderm and ectoderm markers, but a significant decrease was observed in meso-dermmarker expression([Figure 2A](#F2){ref-type="fig"}).Consistent with these results, expression of an HA-tagged Maf1 construct resulted in enhanced expression of both T mRNA and protein ([Figures 2B and 2C](#F2){ref-type="fig"}). These results indicate that Maf1 facilitates cell fate commitment of mouse EBs (mEBs) to into the mesoderm germ layer.

Maf1 Promotes the Differentiation of mESCs into Terminally Differentiated Adipocytes {#S4}
------------------------------------------------------------------------------------

As Maf1 is involved in regulating lipid homeostasis ([@R24]; [@R31]), and adipocytes are a derivative of the mesoderm lineage, we examined whether Maf1 knockdown in mESCs and the impairment of mesoderm induction might further affect the terminal differentiation of these cells into adipocytes. Decreased Maf1 expression by two different shRNAs in the mESCs resulted in an increase in RNA pol III-generated transcripts ([Figure 3A](#F3){ref-type="fig"}). These cells were then programmed to undergo terminal adipocyte differentiation ([Figure S1A](#SD1){ref-type="supplementary-material"}). At day 22, pre-tRNA^Leu^ and U6 RNA transcripts were significantly reduced, even in cells that were expressing the Maf1 shRNAs. However, reduced Maf1 expression resulted in a significant decrease in the number of adipocyte colonies ([Figure 3C](#F3){ref-type="fig"}). This was not due to a change in cell number or viability, as the control and Maf1-knockdown cells showed no detectable difference. The change in adipocyte colonies corresponded to a reduction in the expression of two key adipogenic inducers, PPARγ and C/EBPα, and their downstream targets FABP4 and perilipin ([Figures 3B and 3C](#F3){ref-type="fig"}). These results support the idea that Maf1 promotes mESCs to terminally differentiate into adipocytes.

Maf1 Induces Pro-adipogenic Gene Expression and Enhances Adipocyte Differentiation {#S5}
----------------------------------------------------------------------------------

The observed impairment in adipogenesis by decreased Maf1 expression could be a result of changes in mesoderm induction, which then leads to altered adipogenesis, or Maf1 may additionally play a role in the terminal differentiation of preadipocytes. To address this, we differentiated 3T3-L1 preadipocyte cells into adipocytes ([Figure S1B](#SD1){ref-type="supplementary-material"}). Maf1 protein expression was increased during the differentiation process (Figures [4B](#F4){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). However, a reproducible increase in tRNA gene transcripts was also observed (Figures [4A](#F4){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}), suggesting that other factors are determining the overall rate of tRNA synthesis as the 3T3-L1 cells differentiate into adipocytes. Knockdown of Maf1 expression by two different shRNAs in the preadipocytes resulted in an initial slight increase in tRNA gene transcripts that was also marginally increased upon differentiation (Figures [4A](#F4){ref-type="fig"} and [S2A](#SD1){ref-type="supplementary-material"}). However, decreased Maf1 expression significantly limited the induction of adipogenic gene mRNAs and proteins ([Figures 4A, 4B](#F4){ref-type="fig"}, [S2A, and S2B](#SD1){ref-type="supplementary-material"}). Maf1 knockdown further resulted in a corresponding decrease in adipocyte differentiation (Figures [4C](#F4){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). These results indicate that Maf1 not only functions to enhance the induction of ESCs to form mesoderm but independently drives the terminal differentiation of preadipocytes.

To further confirm a role for Maf1 in adipogenesis, we differentiated *Maf1*^−/−^ MEFs into adipocytes ([Figure S1C](#SD1){ref-type="supplementary-material"}). Few small adipocyte colonies were observed when the *Maf1*^−/−^ MEFs were programed to differentiate into adipocytes ([Figure 5C](#F5){ref-type="fig"}). Ectopic expression of Maf1 in these cells resulted in a significant decrease in tRNA transcripts throughout the differentiation process. Furthermore, an increase in the expression of the pro-adipogenic gene mRNAs and protein was observed, correlating with an increase in adipocyte formation ([Figures 5A--5C](#F5){ref-type="fig"}). Induction of Maf1 expression for only the first 3 days was sufficient to drive this increase in adipogenesis ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}), suggesting that Maf1 acts early in this process to facilitate adipocyte formation. We further determined how a reduction in Maf1 expression in 3T3-L1 cells would affect their ability to form fat tissue *in vivo*. 3T3-L1 cells expressing either control shRNA or Maf1 shRNA were injected into the sternum of athymic mice. Among four mice injected with cells expressing the control shRNA, three developed visible fat pads in the region of the injection. In contrast, none of the mice expressing the shRNA-targeting Maf1 developed visible fat pads ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}). Collectively, these results demonstrate a role for Maf1 in promoting adipocyte differentiation.

Inhibition of RNA Pol III-Mediated Transcription Enhances Adipogenesis {#S6}
----------------------------------------------------------------------

As a well-established function of Maf1 is to repress RNA pol III-dependent transcription, we asked whether the observed Maf1 mediated changes in this transcription process contribute to its ability to influence adipocyte differentiation. To do so, we first used an RNA pol III-specific chemical inhibitor, ML-60218 ([@R43]). Preadipocytes were treated with ML-60218 for 1 day prior to the administration of the differentiation cocktail, and it was removed 2 days later ([Figure S1D](#SD1){ref-type="supplementary-material"}). A dose-dependent increase in adipogenesis was observed upon inhibitor treatment ([Figure S4](#SD1){ref-type="supplementary-material"}). At the higher inhibitor concentrations, a modest but reproducible decrease in tRNA gene transcripts was initially observed with ML-60218 treatment, but there was no difference in the amount of these transcripts in the terminally differentiated cells treated with ML-60218 compared with control untreated cells ([Figure 6A](#F6){ref-type="fig"}). Inhibitor treatment resulted in enhanced expression of PPARγ, C/EBPα, and FABP4 mRNA and protein ([Figures 6A and 6B](#F6){ref-type="fig"}) corresponding to an increase in adipocyte formation ([Figure 6C](#F6){ref-type="fig"}). To verify these results, a second approach was used to repress RNA pol III-dependent transcription. Downregulation of Brf1, an RNA pol III-specific TFIIIB transcription factor subunit ([Figure S1E](#SD1){ref-type="supplementary-material"}), in the 3T3-L1 cells produced a decrease in tRNA transcripts prior to differentiation but not after differentiation of the cells ([Figure 6D](#F6){ref-type="fig"}). Decreases in Brf1 expression resulted in enhanced induction of the pro-adipogenic genes and adipocyte formation ([Figures 6E and 6F](#F6){ref-type="fig"}). We further examined whether these results could be recapitulated in primary cells. Mouse subcutaneous inguinal fat was isolated, and cells obtained from the stromal vascular fraction (SVF) were examined for their ability to differentiate into adipocytes ([Figures S1F and S1G](#SD1){ref-type="supplementary-material"}). Treatment with ML-60218 enhanced adipocyte formation, as did transfection of these cells with Brf1 small interfering RNAs (siRNAs) to knock down Brf1 expression ([Figures S5A--S5D](#SD1){ref-type="supplementary-material"}). Our collective results support the idea that at least one mechanism by which Maf1 functions to stimulate adipogenesis is through its ability to repress RNA pol III-dependent transcription.

Altered Maf1 Expression Produces a Distinct Gene Expression Signature Compared with Inhibition of RNA Pol III-Dependent Transcription by Inhibitor Treatment or Brf1 Knockdown {#S7}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Because our results indicated that changes in RNA pol III-dependent transcription alter cellular mRNA expression, specifically PPARγ and C/EBPα, to enhance adipogenesis, we further determined how Maf1 might regulate PPARγ expression or activity. Ectopic expression of PPARγ in 293T cells was used to analyze PPARγ-mediated transactivation of a promoter containing PPARγ-binding elements ([Figure S6](#SD1){ref-type="supplementary-material"}). These results revealed that Maf1 does not affect the ability of PPARγ to stimulate transcription in the presence or absence of rosiglitazone, a PPARγ agonist, indicating that Maf1 does not directly regulate PPARγ activity. To further identify other Maf1- and RNA pol III-mediated changes in gene expression that control adipogenesis in 3T3-L1 cells, RNA-seq analysis was conducted. Confluent cells were plated and harvested prior to the addition of the differentiation cocktail (day 0) or 2 days after its addition (day 2). Changes in gene expression produced by Maf1 knockdown (shMaf1), Brf1 knockdown (shBrf1), or ML60218 (ML) treatment were first analyzed prior to the addition of the differentiation cocktail. shMaf1 produced 1,108 differentially regulated transcripts, while RNA pol III-compromised cells (shBrf1 cells and cells treated with ML-60218) showed only a few genes with changed expression ([Figure 7A](#F7){ref-type="fig"}, top). Gene function analyses showed that Maf1-sensitive genes enriched for a distinct, cell cycle-centric biology at day 0 ([Table S1](#SD1){ref-type="supplementary-material"}). Analysis of the changes in gene expression incurred by Maf1 knockdown that corresponded to reciprocal changes in gene expression by Brf1 knockdown or ML-60218 treatment also revealed that each of these conditions yielded relatively distinct changes in gene expression ([Figure 7B](#F7){ref-type="fig"}, left). Although it is possible that the observed Maf1-specific changes result from its ability to differentially affect the production of RNA pol III-derived transcripts, these discernible Maf1-specific changes in gene expression may result from Maf1 regulating RNA pol II-dependent gene transcription, as evidence supports that mammalian Maf1 can be recruited to certain RNA pol II-dependent promoters ([@R22]; [@R26]; [@R27]; [@R31]). Genome-wide analysis of Maf1 chromatin occupancy has been problematic, but recent chromatin immunoprecipitation sequencing (ChIP-seq) analysis showed that it is only very weakly enriched at RNA pol II-driven genes compared with what is observed for its binding at RNA pol III-transcribed genes (Orio[@R27]). Our results are nevertheless consistent with the idea that in addition to its ability to selectively regulate mRNA expression through repression of RNA pol III-mediated transcription, Maf1 is capable of regulating mRNA expression in a manner that is distinct from its role in repressing genes that are directly transcribed by RNA pol III.

Altered Maf1 Expression and RNA Pol III Transcription Repression during Adipogenesis Produce Overlapping Gene Signatures for Adipocyte Differentiation and Lipid Metabolism {#S8}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gene expression analysis at 2 days following the addition of the differentiation cocktail revealed that all samples displayed robust numbers of differentially regulated transcripts ([Figure 7A](#F7){ref-type="fig"}, bottom). Maf1 knockdown-mediated changes indicate that the enrichments at day 2 were different from the biology indicated at day 0, prior to the addition of the differentiation cocktail ([Table S1](#SD1){ref-type="supplementary-material"}). Although all three conditions affected the production of RNA pol III-derived transcripts, there were both overlapping and distinct sets of genes that were altered by Maf1 knockdown, Brf1 knockdown, and ML-60218 treatment during adipogenesis ([Figure 7B](#F7){ref-type="fig"}, right). Maf1 downregulation altered the expression of genes involved in lipid and sugar metabolism that overlaps with RNA pol III-compromised 3T3-L1 cells undergoing differentiation ([Table S2](#SD1){ref-type="supplementary-material"}). Enriched gene function analyses were conducted using major databases for gene-function associations and gene signatures. This revealed that shMaf1 downregulated transcripts that were concurrently upregulated by shBrf1 and ML-60218 treatment enriched for fat cell differentiation, lipid metabolism, glucose homeostasis, PPARγ, and adipocytokine signaling pathways. This gene signature after 2 days of cell differentiation overlapped with hallmark gene set enrichment analysis (GSEA) gene sets of adipogenesis and of fatty acids metabolism ([Table S2](#SD1){ref-type="supplementary-material"}).

RNA Pol III Regulates Non-coding H19 RNA and Wnt6 Expression {#S9}
------------------------------------------------------------

To further validate the RNA pol III-targeted genes in the RNA-seq analysis that contribute to its ability to regulate adipogenesis, we examined two candidate genes, the lnc RNA H19 and Wnt6, both of which were induced by RNA pol III-mediated transcription. Wnt6 is an established negative regulator of adipogenesis through its ability to induce β-catenin signaling ([@R9]). LncRNA H19, transcribed by RNA pol II ([@R7]), was also shown to inhibit adipogenesis in mesenchymal stem cells (MSCs) by inhibiting the expression of class II histone deacetylases ([@R19]). We confirmed that a significant induction of lncRNA H19 expression by Maf1 knockdown was observed both before and after the addition of the differentiation cocktail, whereas RNA pol III-compromised cells displayed a decrease in lncRNA H19 expression ([Figure 7C](#F7){ref-type="fig"}). This indicates that changes in RNA pol III-mediated transcription alter the expression of these genes, independent of the adipogenesis process, and are not just a consequence of the cells' undergoing adipocyte differentiation. Similarly, inhibition of RNA pol III also decreased Wnt6 expression whereas Maf1 knockdown induced its expression both before and during the differentiation process ([Figure 7D](#F7){ref-type="fig"}). Thus, RNA pol III-mediated transcription positively regulates both lncRNA H19 and Wnt6 expression.

DISCUSSION {#S10}
==========

Emerging evidence supports the idea that aberrations in RNA pol III and its transcription components can affect human developmental programs. Mutations in RNA pol III subunits are associated with a variety of human developmental diseases, including leukodystrophy ([@R11]; [@R36]) and Treacher Collins syndrome ([@R12]). Mutations in *BRF1*, encoding a TFIIIB transcription factor subunit, were shown to be causal for human cerebellar-facial-dental syndrome ([@R6]; [@R20]), whereas mutation in *BDP1*, another TFIIIB subunit, was associated with hereditary hearing loss ([@R17]). Several studies have further indicated a role for RNA pol III in cellular differentiation and development. The RNA pol III subunit POLR3G is highly expressed in hESCs compared with differentiated cells ([@R14]), and its decreased expression results in a loss of hESC pluripotency and the formation of all three germ layers ([@R41]). Expression of a splice mutant of the POLR3B subunit in zebrafish led to a disruption in the digestive organ and size reductions in other organs ([@R44]). Furthermore, deficiency of *rpc9*, another RNA pol III subunit, impaired hematopoietic stem and progenitor cell development in zebrafish ([@R40]). How specific changes in RNA pol III-dependent transcription affect these processes remains undetermined.

Our results reveal a role for Maf1, a central repressor of RNA pol III-dependent transcription, in the conversion of mESC to mesoderm. Reduced Maf1 expression in mESCs initiate increases in RNA pol III-mediated transcription and inhibits mesoderm-specific marker gene expression during mEB formation. Previous studies examined the genomic distribution of RNA pol III in mouse and hESCs ([@R1]; [@R8]). The occupancy of RNA pol III in hESCs was found to be a consequence of the more active or permissive chromatin state in these cells ([@R1]). This was shown to be determined, at least in part, by the expression of the pluripotency transcription factors as well as RNA pol II-mediated activity. In addition, there were more tRNA genes occupied overall by RNA pol III in undifferentiated cells than in more highly differentiated cells. Our results indicate that although there was an initial increase in RNA pol III-derived transcripts as mESCs differentiated into EBs, more highly differentiated adipocytes displayed a decrease in transcript levels compared with that observed in mESCs. Thus, our collective results suggest that dynamic changes in RNA pol III-mediated transcription occur during the commitment of mESCs into the different germ layers and that Maf1 may serve to regulate the activity and genomic distribution of RNA pol III at different stages of differentiation.

Our studies have identified a novel role for Maf1 and RNA pol III-mediated transcription repression in the terminal differentiation of cells into adipocytes. Adipogenesis is controlled by a complex and highly orchestrated gene expression program. In mammalian cells, PPARγ and C/EBPα are considered the key early master regulators of adipogenesis ([@R35]; [@R34]). Decreased Maf1 expression impaired both the induction of these adipogenic genes and the ability of these cells to form lipid-producing adipocytes in both mESCs and preadipocytes. Importantly, repression of RNA pol III alone is capable of stimulating adipocyte formation, indicating that the activity of RNA pol III modulates adipogenesis. RNA-seq analysis revealed a substantial overlapping enrichment of genes involved in adipogenesis and fat metabolism that are induced during the differentiation process upon Maf1 knockdown that corresponds to reciprocal changes with Brf1 knockdown or RNA pol III inhibitor, ML-60218, treatment. Interestingly, in addition to the subset of overlapping changes in gene expression observed with Maf1 knockdown, ML-60218 treatment, or Brf1 knockdown, we find distinct changes in gene expression elicited by manipulating RNA pol III-dependent transcription by these three different approaches. Although no analyses to date have examined how various strategies to modulate RNA pol III-dependent transcription might affect the expression of RNA pol II-dependent genes, our results indicate that the use of different approaches to manipulate this process do not necessarily produce uniform changes in gene expression.

Recent studies showed that mice with whole-body deletion of Maf1 do not exhibit gross phenotypic changes that might be expected with impaired mesoderm induction ([@R5]). This result suggests that in contrast to what we observed *in vitro* with decreased cellular Maf1 amounts, in the context of a whole-body deletion, total loss of Maf1 may result in compensatory changes, likely compounding its important role in homeostasis. Although there was a significant increase in tRNA precursors in the *Maf*^−/−^ mice, the mature steady-state levels of tRNAs were comparable with the wild-type mice. These mice do not accumulate hepatic lipids under a high-fat diet to the same extent as wild-type mice. This effect was attributed to the robust increase in tRNA precursors and high demand for nucleotides, creating metabolic inefficiency. This futile cycling of nucleotides and lipids may preclude the ability to observe potential changes in adipocyte formation in this mouse model. In contrast to that observed in the *Maf*^−/−^ mice, manipulation of Maf1 expression was shown to negatively regulate intracellular lipid accumulation both in C. elegans and in mouse liver ([@R24]; [@R31]). Although more studies are needed to understand the complex role of Maf1 in lipid metabolism, the present collective work suggests the idea that Maf1 can modulate the production of mature adipocytes and it also functions to maintain lipid homeostasis.

In addition to PPARγ and C/EBPα, analysis of RNA pol III-regulated genes that contribute to its ability to inhibit adipogenesis revealed an unexpected role for this transcription process in positively controlling RNA pol II-generated transcripts, Wnt6 and lncRNA H19. Wnts play a particularly crucial role in adipogenesis. Wnt ligand activation of β-catenin inhibits adipogenesis by inducing nuclear β-catenin expression and preventing the induction of C/EBPβ, C/EBPα, and PPARγ ([@R32]). Wnt6 is a potent regulator of MSC fate, and its expression significantly impairs adipocyte formation in both 3T3-L1 preadipocytes and the bone marrow-derived stroma ST2 cell line by repressing PPARγ expression ([@R9]). We further identified lncRNA H19 as another gene target that is responsive to changes in RNA pol III-mediated transcription. In MSCs, lncRNA H19 expression inhibits adipogenesis ([@R19]). This occurs, at least in part, through the ability of lncRNA H19, and its encoded miR-675, to downregulate the expression of several class II histone deacetylases. Consistent with its inhibitory role in adipogenesis, we find that repression of RNA pol III-mediated transcription decreased expression of lncRNA H19. Collectively, our studies demonstrate that RNA pol III controls the expression of both coding and non-coding RNAs that negatively regulate adipogenesis. In addition, as Wnts ([@R32]) and lncRNA H19 ([@R19]; [@R28]) also play positive roles in osteoblast differentiation, our results suggests the intriguing idea that RNA pol III-dependent transcription could potentially regulate other cell fate decisions.

As RNA pol III regulates various coding and non-coding RNAs to promote adipogenesis, it is likely that multiple mechanisms are involved in producing these changes. Changes in bona fide RNA pol III transcripts could contribute to the observed changes in mRNAs. Modulation of RNA pol III-derived transcripts involved in RNA pol II transcript processing, splicing, and transcription elongation could lead to the observed changes in mRNA and non-coding RNA expression. Alterations in the population of cellular tRNAs have been recently shown to change cellular growth properties by regulating the translation and stability of select mRNAs on the basis of codon use ([@R16]; [@R18]). The availability of enzymes that modify tRNAs may further determine the population of functional tRNAs ([@R2]; [@R29]). In addition, recent studies have identified a role for tRNA-derived small RNAs that regulate ribosome biogenesis ([@R25]). However, the observed RNA pol III-mediated changes in H19 lnc RNA suggest that the regulation of adipogenesis by RNA pol III is not only through changes in tRNAs. RNA pol III-transcribed gene activity has been shown to affect the transcription of RNA pol II-transcribed genes. A positive correlation of actively transcribed RNA pol II genes has been observed with nearby RNA pol III genes or with the recruitment of subsets of RNA pol III transcription components ([@R42]). Recent studies further showed that tRNA genes can organize in clusters via DNA loops that connect distal tRNA genes and RNA pol II-transcribed genes to dynamically coordinate gene activity ([@R39]). Collectively, alterations in RNA pol III-dependent gene activity can have numerous consequences on the expression of RNA pol II-transcribed mRNA and non-coding RNA transcripts. Their possible contributions to RNA pol III-mediated effects on adipogenesis remain to be tested in future studies.

EXPERIMENTAL PROCEDURES {#S11}
=======================

Further detailed experimental procedures are provided in the [Supplemental Information](#SD1){ref-type="supplementary-material"}.

Cell Culture {#S12}
------------

46C mESCs were cultured in Glasgow's modified essential medium (GMEM) supplemented with 15% ESC-qualified fetal bovine serum (FBS), 0.1 mM MEM non-essential amino acids (NEAA), 2 mM GlutaMax, 1 mM sodium pyruvate, 0.1 mM β-mercaptoethanol, 1% penicillin/streptomycin, and 100 U/mL LIF. H9 hESCs were maintained in MEF-conditioned medium consisting of DMEM/F12 supplemented with 20% knockout serum replacement, 0.1 mM MEM NEAA, 0.1 mM β-mercaptoethanol, 1% penicillin/streptomycin, and 4 ng/mL recombinant human FGF2. 3T3-L1 mouse preadipocyte, MEF, and HEK293T cells were maintained in DMEM-HG supplemented with 10% FBS, 2 mM GlutaMax, and 1% penicillin/streptomycin. SVF cells were cultured in DMEM/F12 supplemented with 10% FBS, 2 mM GlutaMax, and 1% penicillin/streptomycin. All cells were cultured in incubators with 5% CO~2~ at 37°C.

Production of Lentiviral Constructs {#S13}
-----------------------------------

Lentiviral particles were produced as described previously ([@R31]) and in the [Supplemental Information](#SD1){ref-type="supplementary-material"}.

*In Vitro* Differentiation of ESCs {#S14}
----------------------------------

For mouse EB formation, mESCs were dissociated with Accutase. mESCs (150,000 cells/mL) were cultured in mESC medium without LIF in six-well Ultra-Low attachment plates. For human EB formation, hESCs (100,000 cells/mL) were cultured in DMEM/F12 supplemented with 10% FBS in 6-well Ultra-Low attachment plates. For both mouse and human EBs, media were changed every other day.

Differentiation of mESCs, 3T3-L1, MEF, and SVF Cells into Adipocytes {#S15}
--------------------------------------------------------------------

Differentiation conditions of mESCs, 3T3-L1, MEF, and SVF cells into adipocytes are described in the [Supplemental Information](#SD1){ref-type="supplementary-material"} and [Figure S1](#SD1){ref-type="supplementary-material"}.

RNA Pol III Inhibitor Treatment {#S16}
-------------------------------

The RNA Pol III chemical inhibitor ML-60218 (Millipore) was dissolved in DMSO at a final concentration of 25 mM. The inhibitor was added to the cells at 20 or 40 μM 1 day before the differentiation cocktail was added and removed 2 days later. The control cells were treated with an equal volume of DMSO.

RNA Isolation and Real-Time qPCR {#S17}
--------------------------------

Total RNA was isolated from cells using the Zymo Directzol RNA Kit. The RNAs were then reverse-transcribed into cDNA with the Superscript III first strand synthesis kit (Invitrogen). Real-time qPCR was performed on the LightCycler 480 (Roche) with the SYBR fast qPCR kit (KAPA Biosystems). Relative amount of transcripts were quantified by comparative threshold cycle method (ΔΔCt) with GAPDH or β-actin as the endogenous reference control. The primers for targets are listed in [Table S3](#SD1){ref-type="supplementary-material"}.

Statistical Analysis {#S18}
--------------------

For statistical analysis, unpaired, two-tailed Student's t tests were used for all comparisons of RNA and oil red O analyses. All results are from three biological and two technical replicates. The fold changes were calculated using controls as described in the figure legends.

Immunoblot Analysis and Antibodies {#S19}
----------------------------------

Cells were washed with DPBS twice, then scrapped and pelleted at 400 × *g* for 5 min. The cells were lysed in triple lysis buffer (50 mM Tris-Cl \[pH 8.0\], 150 mM sodium chloride, 0.02% w/v sodium azide, 1% w/v SDS, 1% v/v NP-40, and 0.5% w/v sodium deoxycholate, containing protease inhibitor cocktail set III; EMD Millipore) for 20 min on ice and sonicated for 15 s. After sonication, the cells were centrifuged for 20 min at 10,000 × *g*, and the supernatant was collected. The protein concentration was determined by using the Bio-Rad Protein *Dc* assay. Cell lysates were subjected to immunoblot analysis and transferred onto a nitrocellulose membrane (GE Healthcare). Membranes were probed using the following antibodies: Maf1 (Abgent), PPARγ, C/EBPα, FABP4, perilipin (Cell Signaling), HA (Roche), T (Santa Cruz), Brf1 (Bethyl), β-actin (Sigma-Aldrich), and α-tubulin (Invitrogen). Protein bands were quantified using Image Lab software (Bio-Rad).

RNA-Seq and Data Analysis {#S20}
-------------------------

Purified RNA was processed for RNA-seq analysis and sent to EAjQ2 Solutions for library preparation and sequencing. Samples were prepared and sequenced according to a standard TS Stranded mRNA sequencing protocol using HiSeq-Sequencing-2×50bp-PE sequencing on an Illumina sequencing platform. RNA samples were converted into cDNA libraries using the Illumina TruSeq Stranded mRNA sample preparation kit (Illumina). Data analysis of RNA-seq is described in the [Supplemental Information](#SD1){ref-type="supplementary-material"}.

De Novo Adipogenesis of 3T3-L1 Cells *In Vivo* {#S21}
----------------------------------------------

For the de novo fat pad formation, the above-described control (pLKO.1-empty vector) and Maf1-knockdown (pLKO.1 Maf1 shRNA-2) 3T3-L1 cells were first grown to confluency. The 1 day post-confluent cells were then trypsinized, and 5 3 10^6^ cells (per mouse) were spun down at 250 3 g for 5 min and resuspended in 200 mL plain DMEM-HG medium. The cell suspensions were injected subcutaneously over the sternum of 8-week-old male athymic mice (The Jackson Laboratory) (institutional protocol \#AN-7016). After 8 weeks, the mice were euthanized, and the skin covering the sternum was examined for the presence of a fat pad. The skin pieces containing fat pads were fixed in neutral-buffered formalin, sectioned cross-wise, and stained with H&E.

Supplementary Material {#SM1}
======================
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![Maf1 Does Not Affect mESC Self-Renewal\
(A) Maf1 protein expression in mESCs and mEBs. mEB1, mEB3, and mEB10 represent the number of days after mEB formation. Protein amounts for the immunoblots were normalized to α-tubulin; fold change was calculated relative to Maf1 protein amounts in mESCs.\
(B) RT-PCR of Maf1 and Oct4 mRNA and Maf1 target genes, tRNA^Leu^ and U6 RNA, in mESCs and mEBs at the indicated days. The amount of transcript was normalized to β-actin. The fold change was calculated relative to the amount of transcripts expressed in mESCs.\
(C) Maf1 expression in hESCs and hEBs at day 14 (hEB14). Protein amounts for the immunoblots were normalized to α-tubulin, and the fold change was calculated relative to the amount of protein in hESCs.\
(D) qRT-PCR analysis of Maf1 and Oct4 mRNA, tRNA^Leu^, and U6 RNA at day 14. The amount of transcript was normalized to β-actin. The fold change was calculated relative to the amount of each transcript in hESCs.\
(E) Immunoblot analysis for Maf1 expression that was decreased in mESCs. Immunoblot analysis of Maf1 protein in control and Maf1 knockdown mESCs normalized to α-tubulin. The fold change in Maf1 expression was calculated relative to protein in control mESCs.\
(F) qRT-PCR analysis of Maf1, U6 RNA, and self-renewal markers, Oct4, SOX2, and Nanog mRNAs in mESCs. The amount of transcript was normalized tob-actin. The fold change was calculated relative to lentivirus-infected control cells.\
(G) Alkaline phosphatase staining of control and Maf1-knockdown mESCs. Scale bar denotes 200 μm.\
(H) Immunostaining images of control and Maf1-knockdown mESCs antibody against SSEA1. Scale bar denotes 100 μm.\
(I) Cell accumulation rates of control and Maf1-knockdown mESCs. Control and Maf1-knockdown mESCs were plated evenly on day 0, and the cell numbers were counted at the indicated days.\
For (B), (D), (F), and (I), data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0002){#F1}

![Maf1 Promotes the Expression of Mesodermal Markers in mEBs\
(A) qRT-PCR analysis of markers associated with the three germ layers (endoderm: GATA6 and GATA4; mesoderm: T and Mesp1; ectoderm: Nestin and SOX1) in control and Maf1-knockdown mESCs and mEBs at the indicated days after cells were infected with either a control lentiviral construct or one harboring an shRNA-targeting Maf1 mRNA.\
(B) qRT-PCR analysis of Maf1, T, and Oct4 in control and Maf1-induced mESCs and mEBs at day 3. mESCs were differentiated into EBs after infection with either a control lentiviral construct (rtTA) or one expressing an HA epitope-tagged Maf1 construct (Maf1-HA). Control and Maf-HA cells were treated with 1 μg/mL doxycycline (dox) 2 days before formation of mEBs and throughout the process of mEB formation. In (A) and (B), data are mean ± SD of n = 3 independent experiments. Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript in control mESCs. \*p \< 0.05, unpaired Student's t test.\
(C) Immunoblot analysis of Maf1-HA, T, and β-actin protein expression in mESCs and mEBs at the indicated days. Protein amounts were normalized to β-actin, and the fold change was calculated relative to the amount of protein in control mESCs.](nihms-1504965-f0003){#F2}

![Maf1 Knockdown Compromises Adipogenesis in mESCs\
Control and Maf1-knockdown mESCs were terminally differentiated into adipocytes following a standard protocol ([Figure S1A](#SD1){ref-type="supplementary-material"}).\
(A) qRT-PCR analysis depicting expression of tRNA^Leu^, U6 RNA, and mRNA for Maf1, PPARγ, C/EBPα, and their target, FABP4, pre- and post-differentiation of mouse mESCs into adipocytes at day 22 (D22). Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript in control mESCs. Cells were infected with lentivirus harboring Maf1 shRNA-1, Maf1 shRNA-2, or a lentivirus that lacks the Maf1 shRNA. Data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.\
(B) Immunoblot analysis for Maf1, PPARγ, C/EBPα, and perilipin in ESCs and at D22 after differentiation (left) and quantification of changes in protein (right). Fold change in Maf1 expression with Maf1 shRNAs was calculated relative to the expression in ESCs, whereas fold change in PPARγ, C/EBPα, and perilipin with Maf1 knockdown was calculated relative to that at D22.\
(C) Representative example of oil red O staining of adipocytes differentiated from control and Maf1-knockdown mESCs (left). Scale bar denotes 200 μm. Quantification of staining (right) represents mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0004){#F3}

![Maf1 Knockdown Reduces Adipogenesis in 3T3-L1 Cells\
Maf1 expression was decreased in 3T3-L1 cells using the lentiviral Maf1 shRNA-2 construct. Lentivirus containing no Maf1 shRNA (control) or Maf1 shRNA-2 (knockdown) was used to infect 3T3-L1 cells, and the cells were terminally differentiated into adipocytes using a standard protocol ([Figure S1B](#SD1){ref-type="supplementary-material"}).\
(A) qRT-PCR analysis for expression of Maf1, tRNA^Leu^, tRNA~i~^Met^, PPARγ, C/EBPα, and FABP4, pre-differentiation at day 0 (D0) and post-differentiation at day 6 (D6). Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript in day 0 control cells. Data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.\
(B) Immunoblot analysis of Maf1, PPARγ, C/EBPα, FABP4, perilipin, and α-tubulin in control and Maf1-knockdown 3T3-L1 cells at the indicated days. Quantification of expression changes for each of the indicated proteins from the immunoblots is shown (right). Protein amounts were normalized to α-tubulin, and the fold change was calculated relative to the amount of protein in D0 control 3T3-L1 cells.\
(C) Oil red O staining of adipocytes differentiated from control and Maf1-knockdown 3T3-L1 cells (left). Scale bar denotes 200 μm. Quantification of staining (right); data represent mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0005){#F4}

![Ectopic Expression of Maf1 Induces Adipogenesis in Maf1^−/−^ MEFs\
*Maf1*^−/−^ MEFs were infected with dox-inducible rtTA construct as control (rtTA) or co-infected with both rtTA and Maf1-HA dox-inducible constructs. Control and Maf1-HA expressed *Maf1*^−/−^ MEFs were terminally differentiated into adipocytes using a standard protocol ([Figure S1C](#SD1){ref-type="supplementary-material"}).\
(A) qRT-PCR analysis of RNA expression of tRNA^Leu^, tRNA~i~^Met^, PPARγ, C/EBPα, and FABP4 during the differentiation of either control or Maf1-HA cells that were all treated with 50 ng/mL dox from day 0 (D0) to day 12 (D12). Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript at D0 rtTA *Maf1*^−/−^ MEF cells. Data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.\
(B) Immunoblot analysis of HA-tagged Maf1, PPARγ, C/EBPα, FABP4, perilipin, and β-actin in control and Maf1 expressed *Maf1*^−/−^ MEF cells. Quantification of the changes in protein expression from the immunoblots is shown (right). Protein amounts were normalized to α-tubulin, and the fold change was calculated relative to the amount of protein in D0 rtTA control *Maf1*^−/−^ MEF cells.\
(C) Oil red O staining of adipocytes that are differentiated from control and Maf1-HA expressed *Maf1*^−/−^ MEFs (left). Scale bar denotes 200 μm. Quantification of staining (right); data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0006){#F5}

![Repression of RNA Pol III-Dependent Transcription by Either ML-60218 Treatment or Brf1 Knockdown Enhances Adipogenesis in 3T3-L1 Cells\
ML-60218-treated and Brf-knockdown 3T3-L1 cells were terminally differentiated into adipocytes using a standard protocol ([Figures S1D and S1E](#SD1){ref-type="supplementary-material"}).\
(A) qRT-PCR analysis of tRNA^Leu^, tRNA~i~^Met^, PPARγ, C/EBPα, and FABP4 mRNAs during the differentiation of DMSO control and ML-60218-treated 3T3-L1 cells at day 0 (D0) and day 6 (D6). Cells were treated with 40 μM of ML-60218 from day 1 to day 2. Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript at D0 in control cells.\
(B) Immunoblot analysis of PPARγ, C/EBPα, FABP4, and β-actin in DMSO control and ML-60218-treated 3T3-L1 cells (left) and quantification of proteins from the immunoblots (right). Protein amounts were normalized to β-actin, and the fold change was calculated relative to the amount of protein at D0 DMSO control cells.\
(C) Oil red O staining of adipocytes differentiated from DMSO control and ML-60218 treated 3T3-L1 cells (left) and quantification of staining (right).\
(D) qRT-PCR analysis of tRNA^Leu^, tRNA~i~^Met^, PPARγ, C/EBPα, and FABP4 mRNAs at D0 before differentiation and at D5 after differentiation of control and Brf1knockdown 3T3-L1 cells. Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript at D0 for control cells.\
(E) Immunoblot analysis of Brf1, PPARγ, C/EBPα, FABP4, and β-actin in control and Brf1-knockdown 3T3-L1 cells (left) and quantification of immunoblots (right). Protein amounts were normalized to β-actin, and the fold change was calculated relative to the amount of protein in D0 for control cells.\
(F) Oil red O staining of adipocytes differentiated from control and Brf1-knockdown 3T3-L1 cells.\
In (A), (C), (D), and (F), data are mean ± SD of n = 3 independent experiments. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0007){#F6}

![Gene Expression Analysis Shows Distinctiveness in the Maf1 Transcriptome Pre-differentiation and an Enriched Gene Signature for Adipogenic Genes during Differentiation\
Differentially regulated transcripts in 3T3-L1 cells that were produced by knockdowns of Maf1, Brf1 (shMaf1 and shBrf1, respectively), or treatment of the cells with the RNA pol III-specific chemical inhibitor ML-60218 (ML).\
(A and B) Before addition of differentiation cocktail (day 0) and 2 days after differentiation induction (day 2). (A) Volcano plot illustration of differentially expressed genes selected on the stringency basis of Student's t test p value % ≤0.01 and ≥1.7-fold change in expression compared with control cells; they are represented by their fold change in log~2~ scale depicted on the × axis and by their statistical significance on the basis of --log~10~ p value shown on the y axis (transcripts with greater statistical significance are higher in the plot). To limit the height of the illustration, --log~10~ p values were capped at 307. (B) Area-proportional Euler Venn diagrams of RNA-seq transcripts shown in the volcano plot data where there are 1,108, 52, and 182 differentially regulated genes for shMaf1, shBrf1, and ML-60218, respectively, plotted for day 0 and 2,016, 2,339, and 1,317 genes for day 2.\
(C and D) qRT-PCR analysis of expression of lncRNA H19 (C) and Wnt6 (D) in control and Maf1-knockdown, control and Brf1-knockdown, and DMSO control and ML-60218-treated 3T3-L1 cells at the indicated days. Transcript amounts were normalized to β-actin, and the fold change was calculated relative to the amount of transcript at D0 for control cells. \*p \< 0.05, unpaired Student's t test.](nihms-1504965-f0008){#F7}

###### Highlights

-   The transcriptional repressor Maf1 promotes mesoderm induction of mESCs

-   Maf1 represses RNA pol III-mediated transcription to induce adipogenesis

-   Altered RNA pol III activity produce gene signatures for adipocyte differentiation

-   RNA pol III repression reduces Wnt6 and H19lnc RNA expression to enhance adipogenesis
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